DNLI — Denali Therapeutics Inc. stock price, charts and financials

QT54Denali Therapeutics Inc.

Denali Therapeutics Inc. (NASDAQ: DNLI) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
24.64
-0.19-0.75%
OverviewShort InterestFilings
DNLIQT54Denali Therapeutics Inc.·NASDAQ
24.64-0.75%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ADPT+3.49%$25.80VKTX+0.26%$34.35TLX+2.65%$11.82CPRX+0.00%$31.49LEGN+1.04%$20.96PRTC+4.51%$17.38RCUS-0.24%$28.55ELVN-1.26%$59.70
Snapshot
Index-P/E-EPS (ttm)-0.96Insider Own27.39%Shs Outstand158.71MPerf Week7.86%
Market Cap3.94BForward P/E-EPS next Y-2.44Insider Trans0.00%Shs Float148.71MPerf Month-8.75%
Enterprise Value3.77BPEG5.11EPS next Q-Inst Own-Short Float10.78%Perf Quarter25.98%
Income-433.48MP/S-EPS this Y-150.83%Inst Trans-Short Ratio8.47Perf Half Y24.03%
Sales3.60MP/B5.57EPS next Y-1.29%ROA-44.17%Short Interest16.04MPerf YTD50.39%
Book/sh-P/C-EPS next 5Y-ROE-55.27%52W High27.10 -9.05%Perf Year73.03%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-50.82%52W Low12.49 97.38%Perf 3Y-9.91%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin-158.46%Volatility3.89% 4.95%Perf 5Y-51.34%
Dividend TTM-EV/Sales-EPS Y/Y TTM62.65%Oper. Margin-15058.19%ATR (14)1.11Perf 10Y-
Dividend Ex-Date-Quick Ratio8.32Sales Y/Y TTM-Profit Margin-14191.20%RSI (14)56.65Recom2.00
Dividend Gr. 3/5Y-Current Ratio8.37EPS Q/Q11.54%SMA204.50%Beta0.99Target Price34.57
Payout0.00%Debt/Eq0.03Sales Q/Q-SMA506.13%Rel Volume0.94Prev Close24.83
Employees503LT Debt/Eq0.03EarningsNov 05SMA20023.94%Avg Volume1.86MPrice24.64
IPO DateDec 08, 2017Option/ShortYes / YesEPS/Sales Surpr.4.61% -Net Debt/EBITDA0.35Volume1,749,186Change-0.75%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedUBSBuy$25 → $34
Aug-07-26ReiteratedRobert W. Baird$31 → $34
Jul-23-26ReiteratedMorgan StanleyOverweight$35 → $36
Jul-13-26ReiteratedWedbushOutperform$20 → $26
Jun-22-26ReiteratedStifel Nicolaus$37 → $41
May-22-26ReiteratedDeutsche Bank$35 → $31
May-08-26ReiteratedWedbushOutperform$30 → $23
Mar-26-26ReiteratedDeutsche Bank$26 → $35
Mar-02-26ReiteratedJefferiesBuy$45 → $40
Jan-08-26ReiteratedMorgan StanleyOverweight$32 → $40
Latest News
Aug-07-26
Aug-07-2603:41PM
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentumzacks.com
03:44AM
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-06-26
Aug-06-2609:04PM
Denali Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
06:41PM
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimateszacks.com
04:01PM
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlightsglobenewswire.com
Jul-27-26
Jul-27-2604:01PM
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026globenewswire.com
Jul-23-26
Jul-23-2602:04PM
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36Benzinga
Jul-16-26
Jul-16-2607:45AM
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35Benzinga
Jul-15-26
Jul-15-2602:06PM
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?zacks.com
Jul-13-26
Jul-13-2607:03AM
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price TargetBenzinga
Jul-09-26
Jul-09-2604:01PM
Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrierglobenewswire.com
Jul-08-26
Jul-08-2603:05PM
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?zacks.com
Jun-18-26
Jun-18-2608:07AM
Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195MBenzinga
Company

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
34000——————
Cost of Goods Sold Incl. D&A0110——————
Gross Profit340-110——————
Selling, General and Administrative Excl. Other10297105——————
Research and Development409419396——————
Other Operating Expense028-14——————
Operating Income-170-555-487——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)454365——————
Net Income Before Taxes-125-512-423——————
Income Taxes
000——————
Consolidated Net Income-125-513-423——————
Net Income From Continuing Operations-125-513-423——————
Net Income-125-513-423——————
EPS (Recurring)-0.92-2.97-2.57——————
EPS (Basic, Before Extraordinaries)-0.92-2.97-2.57——————
EPS (Diluted)-0.96-2.97-2.57——————
EBITDA-106-498-493——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
10.00————————
Gross Margin
100.00————————
Operating Margin
-50.00————————
Net Margin
-36.76————————
Shares Outstanding138175164——————
Market Capitalization3,4012,8893,342——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$29.38$24.68$19.98$15.28$10.58● Close Price0.00K216.22K432.43K648.65K864.86KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Watts Ryan J.President and CEOJan 06 '26Sale16.5035,198580,767296,833Jan 08
Schuth Alexander O.COFO and SecretaryJan 06 '26Sale16.5017,218284,097282,828Jan 08
BAKER BROS. ADVISORS LPDirectorDec 11 '25Buy0.012,285,71422,85725,996,310Dec 15
Ho CaroleChief Medical OfficerAug 13 '25Sale14.6480611,800216,585Aug 14
Schuth Alexander O.COFO and SecretaryAug 12 '25Sale13.582,93739,884242,346Aug 14
Ho CaroleChief Medical OfficerAug 12 '25Sale13.582,93739,884217,391Aug 14
Ho CaroleChief Medical OfficerAug 05 '25Option Exercise0.6844,65530,365220,328Aug 07
Watts Ryan J.President and CEOJul 09 '25Option Exercise1.05495,282520,792748,353Jul 11
Watts Ryan J.President and CEOJul 09 '25Sale15.00495,2827,429,230253,071Jul 11
Ho CaroleChief Medical OfficerJan 07 '25Sale20.812,90760,495175,673Jan 08
Schuth Alexander O.COFO and SecretaryJan 07 '25Sale20.812,90760,495244,308Jan 08
Watts Ryan J.President and CEOJan 07 '25Sale20.817,650159,197253,071Jan 08
Krognes Steve E.DirectorJan 07 '25Sale20.813,33969,48525,757Jan 08
Watts Ryan J.President and CEOJan 06 '25Sale20.2229,266591,759260,721Jan 08
Ho CaroleChief Medical OfficerJan 06 '25Sale20.2212,255247,796178,580Jan 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.